Well, no mention on pharmaceuticals. Did they lose or make money? They're too reactive and not proactive enough in an overwhelming majority of genericized market. They have good products but fail to understand the market dynamics on how to promote, develop relationships with specialty/compounding pharmacies, and work with physician on an aged line molecules that actually work well. If they keep going
in the same direction, this will not age well imo even with new products 1-2 yrs from now. The old/current model of managed care reliance will no longer work for the most part if you want to be profitable. The will scalp you on the way in out for maybe a couple market share points. They need to more cutting edge and develop a plan on getting widespread unencumbered access to patients and making the doctors comfortable with the price points to get behind the products enough to prescribe 1st/2nd line.
RECENT NEWS:
VAUGHAN, ON, June 8, 2022 /CNW/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company" or "we"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2022 financial results.
"In the first quarter, Bausch + Lomb delivered organic revenue1,2 growth, driven by our two largest segments, Vision Care and Surgical," said Joseph C. Papa, chairman and CEO, Bausch + Lomb. "Bausch + Lomb has always stood at the forefront of cutting-edge scientific and technological optical advancements, and today we are more focused than ever on developing and offering new treatments to meet unmet eye health needs."
"As we look to the future as a publicly traded company, we believe we are well positioned for growth in large, durable markets, driven by new products and megatrends, and we see many attractive opportunities for a pure-play eye health company," continued Mr. Papa.
in the same direction, this will not age well imo even with new products 1-2 yrs from now. The old/current model of managed care reliance will no longer work for the most part if you want to be profitable. The will scalp you on the way in out for maybe a couple market share points. They need to more cutting edge and develop a plan on getting widespread unencumbered access to patients and making the doctors comfortable with the price points to get behind the products enough to prescribe 1st/2nd line.
RECENT NEWS:
VAUGHAN, ON, June 8, 2022 /CNW/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company" or "we"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2022 financial results.
"In the first quarter, Bausch + Lomb delivered organic revenue1,2 growth, driven by our two largest segments, Vision Care and Surgical," said Joseph C. Papa, chairman and CEO, Bausch + Lomb. "Bausch + Lomb has always stood at the forefront of cutting-edge scientific and technological optical advancements, and today we are more focused than ever on developing and offering new treatments to meet unmet eye health needs."
"As we look to the future as a publicly traded company, we believe we are well positioned for growth in large, durable markets, driven by new products and megatrends, and we see many attractive opportunities for a pure-play eye health company," continued Mr. Papa.